| 000 | 01589 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515115421.0 | ||
| 264 | 0 | _c20080604 | |
| 008 | 200806s 0 0 eng d | ||
| 022 | _a1471-2474 | ||
| 024 | 7 |
_a10.1186/1471-2474-9-52 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlonso-Ruiz, Alberto | |
| 245 | 0 | 0 |
_aTumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. _h[electronic resource] |
| 260 |
_bBMC musculoskeletal disorders _cApr 2008 |
||
| 300 |
_a52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Review; Systematic Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xtherapeutic use |
| 700 | 1 | _aPijoan, Jose Ignacio | |
| 700 | 1 | _aAnsuategui, Eukene | |
| 700 | 1 | _aUrkaregi, Arantxa | |
| 700 | 1 | _aCalabozo, Marcelo | |
| 700 | 1 | _aQuintana, Antonio | |
| 773 | 0 |
_tBMC musculoskeletal disorders _gvol. 9 _gp. 52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2474-9-52 _zAvailable from publisher's website |
| 999 |
_c17917533 _d17917533 |
||